U.S. Supreme Court Declines Patent Case on Bausch Diarrhea Drug

The U.S. Supreme Court turned away on Monday a bid by Alvogen’s subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health’s (BHC.TO), blockbuster diarrhea drug Xifaxan.

The justices declined to hear an appeal by Norwich Pharmaceuticals of a lower court’s ruling that its proposed generic would infringe patents owned by Bausch unit Salix Pharmaceuticals for using Xifaxan to treat the liver-related brain disorder hepatic encephalopathy. In doing so, the justices let the lower court’s ruling stand.

Read more at Reuters.